Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...

Stocks like Schaeffler India, GE Power India, Coal India, Servotech Renewable Power System, Chemplast Sanmar, Rail Vikas ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...